Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Lorus Therapeutics Receives Patent Approval For Anticancer Drug LOR-253

Lorus Therapeutics Inc. (LOR.TO: Quote) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.

The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.

The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.

LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.

Click here to receive FREE breaking news email alerts for Lorus Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Germany's unemployment increased unexpectedly in August as worsening economic activity weighed on job creation. In addition, consumer price inflation, at a four-and-a-half-year low, boosted the scope for more stimulus from the European Central Bank. The number of people out of work increased by a seasonally adjusted 2,000 persons to 2.901 million in August, the Federal Labor Agency reported. NASA has approved the development of the world's most powerful rocket, designed to take humans beyond Earth orbit and to Mars. NASA officials Wednesday announced they have completed a rigorous review of the Space Launch System (SLS) -- the heavy-lift, exploration class rocket under development - and approved the program's progression from formulation to development, something no other exploration Eurozone economic confidence weakened more-than-expected in August to its lowest level in eight months, underscoring rising pessimism amid heightened geopolitical tensions and stagnating economic recovery. The economic confidence index fell to 100.6 in August, the lowest score since December, from 102.1 in July, the European Commission said Thursday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.